实惠医疗法案 (ACA) 实施对非霍奇金淋巴瘤存活率的因果影响:差异分析中的差异分析
Oluwasegun A Akinyemi1,2, Terhas Asfiha Weldeslase3, Mojisola E Fasokun4
1Health Policy and Management, University of Maryland School of Public Health, College Park, USA.
Cureus
|January 22, 2024
概括
负担得起的医疗法案 (ACA) 改善了非霍奇金淋巴瘤 (NHL) 患者的癌症存活率,特别是在扩张状态. 这种医疗保健政策干预措施对患者的治疗结果产生了显著的积极影响.
科学领域:
- 在瘤学瘤学.
- 卫生政策 卫生政策
- 流行病学 流行病学
背景情况:
- 非霍奇金淋巴瘤 (NHL) 由于其流行率和死亡率,在美国构成了重大公共卫生挑战.
- 负担得起的医疗法案 (ACA) 可能会通过改善NHL患者的医疗保健和治疗利用来影响癌症存活率.
研究的目的:
- 评估"负担得起的医疗法案" (ACA) 实施对非霍奇金淋巴瘤 (NHL) 患者癌症特异性存活率的影响.
- 为了比较在ACA下扩大医疗补助的州和没有扩大医疗补助的州之间的生存结果.
主要方法:
- 从2000年到2020年使用监测,流行病学和最终结果 (SEER) 登记册进行了回顾性分析.
- 一个差异差异的方法比较佐治亚州 (非扩张) 和新泽西州 (扩张) 的ACA前后实施.
- 根据患者人口统计,社会经济因素,疾病阶段和治疗方式进行调整.
主要成果:
- 在ACA后的时期,生存率有34%的改善.
- 在新泽西州的NHL患者中,ACA的实施与16%的存活率增加有关.
- 手术,放射治疗和婚姻状况也与改善的生存结果有关.
结论:
- 负担得起的医疗法案 (ACA) 与提高非霍奇金淋巴瘤 (NHL) 患者的癌症特异性生存率有关.
- 医疗保健政策改革在改善瘤患者的治疗结果方面发挥着至关重要的作用.
相关概念视频
Cancer Survival Analysis
353
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
353
Comparing the Survival Analysis of Two or More Groups
195
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
195
Actuarial Approach
79
The actuarial approach, a statistical method originally developed for life insurance risk assessment, is widely used to calculate survival rates in clinical and population studies. This method accounts for participants lost to follow-up or those who die from causes unrelated to the study, ensuring a more accurate representation of survival probabilities.
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
79
Introduction To Survival Analysis
239
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
The primary goal of survival analysis is to estimate survival time—the time...
239
Assumptions of Survival Analysis
131
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
131
Kaplan-Meier Approach
146
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
146


